Hormoznejad et al. have assessed the effect of 288 mg of cranberry supplementation for 3 months on cardiometabolic risk factors and steatosis grade in patients with NAFLD and showed a significantly greater reduction of alanine aminotransferase (ALT) and insulin in the cranberry group than in the placebo group. The gene discussed is INS; the disease is metabolic dysfunction-associated steatotic liver disease.